EFFECTIVENESS AND SAFETY OF IXEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

4CPS-324

M.D.P. BRICEÑO CASADO[1], M.D. GIL-SIERRA[2], B. DE LA CALLE RIAGUAS[1], M. DOMINGUEZ-CANTERO[3].
[1]HOSPITAL NUESTRA SEÑORA DEL PRADO, HOSPITAL PHARMACY, TALAVERA DE LA REINA, SPAIN. [2]HOSPITAL DOCTOR JOSE MOLINA OROSA, HOSPITAL PHARMACY, LANZAROTE, SPAIN. [3]HOSPITAL UNIVERSITARIO PUERTO REAL, HOSPITAL PHARMACY, CADIZ, SPAIN.

L04-Immunosuppressive agents

BACKGROUND AND IMPORTANCE

Ixekizumab is a high-affinity monoclonal antibody against interleukin-17A. It is used for treatment of **moderate-to-severe plaque psoriasis** (MTSPP).

AIM AND OBJECTIVES

To assess effectiveness and safety of ixekizumab in MTSPP in clinical practice.

MATERIAL AND METHODS

- Descriptive retrospective multicenter study was conducted.
- Patients with MTSPP receiving ixekizumab between 01/01/2017-30/09/2020 were included.
- Electronic clinical history and prescription program Farmatools® were used to record data: sex, age, previous treatment, dosage and duration of therapy.
- **Effectiveness** → measured by Psoriasis Area Severity Index (PASI): PASI-75 (≥75% reduction in baseline PASI), PASI-90 (≥90% reduction) and PASI-100 (total clearance of lesions) at weeks 12 and 36. Failure to achieve PASI-75 was considered as no response.
- **Safety**→ evaluated according to adverse events (AE) and discontinuations of treatment.



RESULTS

- 46 patients: 27 (59%) men. Mean age = 49 (23-74) years.
- **Induction dose**: 160 mg at week 0, then 80 mg at weeks 2, 4, 6, 8, 10 and 12. **Maintenance**: 80 mg every 4 weeks in 34 (74%) patients and every 6 weeks in 12 (26%).
- **Baseline PASI** >5 in all patients and >10 in 37 (80%) cases.
- **Mean duration** therapy = 17 (3-44) months.

PREVIOUS TREATMENT:
methotrexate (n=33), cyclosporine (n=29) and biological therapy (n=35).
Mean of prior biological drugs was 3 (1-5), including:

- anti-TNF (etanercept, n=23; adalimumab, n=22; infliximab, n=3)
- anti-IL12-23 (ustekinumab, n=16)
- anti-IL17A (secukinumab, n=7)



EFFECTIVENESS → not evaluated in 5 (11%) patients at week 12 and 8 (17%) at week 36 due to lack of information.

- At week 12: one (2%) patient presented PASI-75, 12(26%) PASI-90, 23 (50%) PASI-100 and 5 (11%) no response.
- At week 36: one (2%) patient achieved PASI-75, 15 (33%) PASI-90, 16 (35%) PASI-100 and 6 (13%) no response.

SAFETY PROFILE → 3 (7%) patients presented AE: alopecia, eosinophilia and injection site reaction. No discontinuations of treatment were reported.

CONCLUSION AND RELEVANCE

Ixekizumab was effective and provided a total clearance of MTSPP lesions to half of patients at week 12, showing this considerable response in more than a third of patients at week 36. Ixekizumab was well tolerated, with low frequency of AE.